Next Article in Journal
Preconception and Prenatal Nutrition and Neurodevelopmental Disorders: A Systematic Review and Meta-Analysis
Previous Article in Journal
Evaluation of Athletes’ Food Choices during Competition with Use of Digital Images
Open AccessArticle

Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4

1
Department of Integrated Biosciences edu., Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa 277-8562, Japan
2
Brain Functions Laboratory, Inc., Yokohama 230-0046, Japan
3
Memory Clinic Ochanomizu, Bunkyo-ku, Tokyo 113-0034, Japan
4
Center for Brain Integration Research, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan
5
National Institute of Health and Nutrition, National Institute of Biomedical Innovation, Health and Nutrition, Shinjuku -ku, Tokyo 162-8636, Japan
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(7), 1626; https://doi.org/10.3390/nu11071626
Received: 24 May 2019 / Revised: 12 July 2019 / Accepted: 15 July 2019 / Published: 17 July 2019

Background: Oral supplementation of anserine/carnosine helps preserve cognitive functions in healthy older adults. Mild cognitive impairment (MCI) is a transition between cognitive-normal and dementia. Therefore, it needs to investigate whether anserine/carnosine supplementation (ACS) has effects on subjects with MCI. Methods: A randomized, double-blind, placebo-controlled 12-week trial was performed. Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1). Evaluation of cognitive change was conducted utilizing a psychometric test battery. Results: The score improvement in the global Clinical Dementia Rating (gloCDR) was superior in the active group than placebo (p = 0.023). No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer’s Disease Assessment Scale (ADAS). When APOE4 positive (APOE4 (+)) or negative (APOE4 (-)) subjects were separately analyzed, beneficial change in the APOE4 (+) subjects was observed in MMSE (p = 0.025) as well as in gloCDR (p = 0.026). Conclusions: The present study might suggest that protective effects against cognitive decline in APOE4 (+) MCI subjects exist. View Full-Text
Keywords: Alzheimer’s disease; cognitive functions; anserine and carnosine; randomized controlled trial (RCT); mild cognitive impairment (MCI); APOE4 Alzheimer’s disease; cognitive functions; anserine and carnosine; randomized controlled trial (RCT); mild cognitive impairment (MCI); APOE4
Show Figures

Figure 1

MDPI and ACS Style

Masuoka, N.; Yoshimine, C.; Hori, M.; Tanaka, M.; Asada, T.; Abe, K.; Hisatsune, T. Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4. Nutrients 2019, 11, 1626.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop